348 results on '"De Cecco, Loris"'
Search Results
2. A gene expression-based classifier for HER2-low breast cancer
3. SAA1‐dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness
4. Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial
5. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
6. Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case
7. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: implications for improving treatment modalities
8. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors
9. MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures
10. Case report: biallelic DNMT3A mutations in acute myeloid leukemia
11. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles
12. Supplementary Data Table S2 from JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer
13. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
14. Figure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
15. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
16. Figure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
17. Supplementary Table S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
18. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
19. Figure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
20. Figure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
21. Supplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
22. Supplementary Table S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
23. Figure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
24. Figure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
25. Figure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
26. Figure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
27. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
28. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
29. Figure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
30. Figure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
31. Figure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
32. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
33. Figure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
34. Supplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
35. Figure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
36. Figure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
37. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
38. Medulloblastoma at relapse: for which patients and which tumors reirradiation is the better choice
39. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
40. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
41. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
42. Figure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
43. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
44. Figure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
45. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
46. Figure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
47. Supplementary Table S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
48. Figure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
49. Figure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
50. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.